用于平均风险人群卵巢癌筛查的细胞外囊泡与颗粒血液检测:一项使用临床前样本的嵌套病例对照研究
在UKCTOCS超声与无筛查组的平均风险女性临床前样本中,采用盲法嵌套病例对照设计评估基于免疫PCR的肿瘤相关细胞外囊泡与颗粒(EVP)血液检测。EVP检测对高级别浆液性癌(HGSC)的敏感性为82.9%,特异性为97.7%,CA125敏感性为68.3%、特异性为95.6%。作者认为该检测在临床前样本中具有高敏感性和特异性,支持其作为平均风险女性卵巢癌潜在年度筛查工具进一步评估。
要点
- EVP血液检测在41例HGSC中敏感性82.9%,在1176例对照中特异性97.7%。
- CA125敏感性68.3%(p=0.082)、特异性95.6%(p=0.005),与EVP检测比较。
- Ⅰ/Ⅱ期HGSC中EVP检测敏感性88.9%(8/9),CA125为55.6%(5/9),p=0.149。
核心结论
- EVP血液检测在临床前样本中检测HGSC具有高敏感性和特异性,支持其作为平均风险女性卵巢癌潜在年度筛查工具进一步评估。
研究设计与样本
- 在UKCTOCS超声组和无筛查组内开展盲法嵌套病例对照研究,病例为样本采集后36个月内诊断为卵巢癌的女性。
- 浸润性上皮癌病例按年龄(±2岁)1:10匹配无卵巢癌对照。
- 异常阈值基于既往设定的EVP检测98%特异性和研究用CA125检测的截断值。
- 主要结局为使用28小时内处理、诊断前最多12个月采集的样本检测HGSC的敏感性和特异性。
主要发现
- EVP检测在41例HGSC中敏感性82.9%(95%CI 68.7-91.5%),在1176例对照中特异性97.7%(95%CI 96.7-98.5%)。
- CA125敏感性68.3%(95%CI 53.0-80.4%;p=0.082),特异性95.6%(95%CI 94.2-96.6%;p=0.005)。
- Ⅰ/Ⅱ期HGSC中EVP检测敏感性88.9%(8/9,95%CI 56.5-98.0%),CA125为55.6%(5/9,95%CI 26.7-81.1%),p=0.149。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current ovarian cancer (OC) screening methods lack sufficient sensitivity to detect early-stage disease. We evaluated an immuno-PCR blood test measuring tumor-associated extracellular vesicles and particles (EVPs) in preclinical samples from average-risk women that participated in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). PATIENTS AND METHODS: We conducted a blinded case-control study nested within the ultrasound and no-screening arms of UKCTOCS. Cases were women diagnosed with OC within 36 months of sample collection. Invasive epithelial cancer cases were matched 1:10 by age (±2 years) to controls without OC. Abnormal thresholds were based on previously established 98 % specificity cut-offs for the EVP-based test and a research CA125 assay. Primary outcomes were sensitivity and specificity for detecting high-grade serous carcinoma (HGSC) using samples processed within 28 h and collected up to 12 months before diagnosis. RESULTS: The EVP-based test demonstrated a sensitivity of 82.9 % (95 % CI: 68.7-91.5 %) in 41 HGSC cases and specificity of 97.7 % (95 % CI: 96.7-98.5 %) in 1176 controls. CA125 sensitivity and specificity were 68.3 % (95 % CI: 53.0-80.4 %; p = 0.082) and 95.6 % (95 % CI: 94.2-96.6 %; p = 0.005), respectively. For stage I/II HGSC, EVP-based test sensitivity was 88.9 % (8/9, 95 % CI: 56.5-98.0 %), compared to 55.6 % (5/9, 95 % CI: 26.7-81.1 %) for CA125 (p = 0.149). CONCLUSIONS: The EVP-based blood test exhibits high sensitivity and specificity in detecting HGSC in preclinical samples, supporting its further evaluation as a potential annual screening tool for OC in average-risk women.
引用
- Manning B, Banerjee S, Hawkins TB, et al. Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples. Gynecol Oncol. 2025. PMID: 41135257. doi:10.1016/j.ygyno.2025.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。